An observational study in Metastatic Hormonesensitive Prostate Cancer (mHSPC), sponsored by Bayer. Recruiting at 1 site in Australia. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by Bayer · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Prostatic Neoplasms by Bayer — 11 open to participants now, 16 under way, 1 of them phase 3. Prostatic Neoplasms · Bayer.
Among the 75 studies in Prostatic Neoplasms by Bayer, this one is the 16th largest by planned enrollment of the 40 observational ones that give a count, is one of 3 that started in 2025, is one of 40 observational ones, reaches primary completion later than 3 of the 15 other live ones, and was the 68th registered.
7,053 studies on the registry are indexed under Prostatic Neoplasms; 1,583 are open to participants now.
Browse Prostatic Neoplasms studies →11 of the 75 studies in Prostatic Neoplasms by Bayer are open now, in 12 countries. Recruiting first, the newest first:
Bayer · Sites in China
Ages 18+ · Men only
Bayer · Sites in United States
Ages 55+ · Men only
Bayer · Sites in China
Ages 18+ · Men only
Bayer · Sites in Germany
Ages 18+ · Men only
Bayer · Sites in Belgium, Finland, France and 13 more countries
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,231 Prostatic Neoplasms studies recruiting now, 930 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 14 · Phase 3 8 · Phase 4 2
First in 2004; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 200 across 1,311 observational studies indexed under Prostatic Neoplasms.
Median enrollment 82 across the 34 interventional studies, 700 across the 40 observational. Of the 57 that completed or were terminated, 12 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
4 of the studies in Prostatic Neoplasms by Bayer that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05794906Phase 3BayerA Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies | 2027-07-30 |
| NCT07223372BayerAn Observational Study to Learn More About How Medicines That Block Male Hormones Are Used in People With Prostate Cancer in Australia | 2026-11-30 |
| NCT07672119BayerA Study to Learn About Heart-Related Risks in Elderly Men With Advanced Prostate Cancer Treated With Enzalutamide or Darolutamide | 2027-04-29 |
| NCT06052306BayerA Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) | 2027-06-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 75 studies in Prostatic Neoplasms by Bayer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a retrospective, observational study looking at real-world prescription data in Australia. The study focuses on adult men with metastatic hormone-sensitive prostate cancer (mHSPC), a type of prostate cancer that has spread but still responds to hormone therapy. The main goal is to understand the treatment patterns, characteristics, and outcomes for patients who are receiving a class of drugs called Androgen Receptor Pathway Inhibitors (ARPIs), such as darolutamide, enzalutamide, apalutamide, or abiraterone. These drugs are often used in combination with standard Androgen Deprivation Therapy (ADT). The research will use two large, de-identified Australian prescription databases: the Pharmaceutical Benefits Scheme (PBS) and the NostraData retail pharmacy dataset. By analyzing this information, the study aims to describe how these treatments are being used over time, including what proportion of patients receive doublet therapy (ARPI + ADT) or triplet therapy (ARPI + ADT + docetaxel chemotherapy). It will also describe the characteristics of the patients receiving these therapies, such as their age and location. Secondary goals include understanding how well patients adhere to their prescribed ARPI treatment and tracking any changes in medication dosage over time. Since the study uses existing, anonymized data, there is no direct contact with patients and individual patient consent is not required. The findings will provide valuable real-world insights into the use of ARPIs in Australia, which can help inform clinical practice and improve care for men with mHSPC.
This study is a retrospective, observational analysis of prescription data collected in Australia from real-world data sources: the Pharmaceutical Benefits Scheme (PBS) 10% sample data and NostraData. Target population were adult male mHSPC patients who initiated ARPI therapy within the study period, either in doublet or triplet therapy with ADT and/or docetaxel.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who received darolutamide
Patients who received enzalutamide
Patients who received apalutamide
Patients who received abiraterone/methylprednisolone
Number and proportion of patients taking each ARPI as a percentage of total study population.
Time frame: Retrospective analysis from December 2022 to June 2025
Demographic characteristics of mHSPC patients
Time frame: Retrospective analysis from December 2022 to June 2025
Proportion of days covered (PDC) to understand adherence
Evaluation of treatment adherence from treatment initiation using a proportion of days covered (PDC) analysis. PDC is calculated as the number of days with medication available divided by the total number of days in the observations period, starting from ARPI (Andorgen receptor pathway inhibitor) initiation
Time frame: Retrospective analysis from December 2022 to June 2025
Starting dose and change in dose over time
Time frame: Retrospective analysis from December 2022 to June 2025
Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Nov 2026, 13 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.